Arcutis Biotherapeutics 株価情報 (NASDAQ: ARQT)

最新ニュース Arcutis Biotherapeutics (NASDAQ:ARQT) 株価情報

Arcutis Biotherapeutics

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics Inc

<p>Zynex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.24) by 37.5 percent.  The company reported quarterly sales of $26.58 million which missed the analyst consensus estimate of $30.83 million by 13.79 percent.  This is a 42.88 percent decrease over sales of $46.53 million the same period last year.</p>


Earnings

Earnings Misses

News

ZYXI

Zynex Q1 EPS $(0.33) Misses $(0.24) Estimate, Sales $26.58M Miss $30.83M Estimate

Earnings Beats

AEYE

AudioEye Q1 Adj. EPS $0.15 Up From $0.08 YoY, Sales $9.73M Beat $9.71M Estimate

<p>Civeo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVEO#NYSE">CVEO</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Civeo to report an <strong>earnings per share</strong> (EPS) of $-0.41.</p>
<p>Investors in Civeo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS missed by $0.96, leading to a 2.27% drop in the share price on the subsequent day.</p>
<p>Here's a look at Civeo's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.14</td>
<td>-0.02</td>
<td>0.21</td>
<td>-0.20</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.10</td>
<td>-0.36</td>
<td>0.56</td>
<td>-0.23</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>2.0%</td>
<td>4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745957016_0.png" alt="eps graph" /></p>
<h3>Civeo Share Price Analysis</h3>
<p>Shares of Civeo were trading at $20.09 as of April 28. Over the last 52-week period, shares are down 16.55%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Observations about Civeo</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Civeo.</p>
<p>Civeo has received a total of 1 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $28.0, the consensus suggests a potential 39.37% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Civeo, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Summary of Peers Analysis</h3>
<p>The peer analysis summary provides a snapshot of key metrics for  and Civeo, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Civeo</td>
<td>Buy</td>
<td>-11.62%</td>
<td>$28.11M</td>
<td>-5.81%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Civeo is positioned at the bottom among its peers based on consensus rating. It ranks at the bottom for revenue growth, showing a decline of 11.62%. In terms of gross profit, Civeo's performance is weak compared to its peers. Additionally, its return on equity is negative at -5.81%, indicating lower profitability compared to others in the group.</p>
<h3>Discovering Civeo: A Closer Look</h3>
<p>Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.</p>
<h3>Civeo: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Civeo's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-11.62%</strong>. This indicates a decrease in the company's top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-9.98%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Civeo's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-5.81%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-3.41%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.21</strong>, Civeo adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/CVEO/earnings"><strong>To track all earnings releases for Civeo visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CVEO

Civeo's Earnings Outlook

<p>Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) reported quarterly earnings of $2.02 per share which beat the analyst consensus estimate of $1.85 by 9.19 percent. This is a 260.71 percent increase over earnings of $0.56 per share from the same period last year.  The company reported quarterly sales of $2.20 billion which missed the analyst consensus estimate of $2.52 billion by 12.84 percent.  This is a 103.15 percent increase over sales of $1.08 billion the same period last year.</p>


Expand Energy Q1 Adj. EPS $2.02 Beats $1.85 Estimate, Sales $2.20B Miss $2.52B Estimate

<p><strong>Haverty Furniture Cos</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HVT#NYSE">HVT</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Haverty Furniture Cos will report an <strong>earnings per share</strong> (EPS) of $0.16. </p>
<p>Anticipation surrounds Haverty Furniture Cos's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.32 in the last quarter, leading to a 9.06% increase in the share price on the following day.</p>
<p>Here's a look at Haverty Furniture Cos's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.17</td>
<td>0.47</td>
<td>0.17</td>
<td>0.36</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.49</td>
<td>0.29</td>
<td>0.27</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>9.0%</td>
<td>-7.000000000000001%</td>
<td>1.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745957002_0.png" alt="eps graph" /></p>
<h3>Market Performance of Haverty Furniture Cos's Stock</h3>
<p>Shares of Haverty Furniture Cos were trading at $18.32 as of April 28. Over the last 52-week period, shares are down 40.86%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/HVT/earnings"><strong>To track all earnings releases for Haverty Furniture Cos visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


What's Next: Haverty Furniture Cos's Earnings Preview

<p>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) is looking for Q2 GAAP EPS of $(0.90)-$(0.75)..</p>


Guidance

BGFV

Big 5 Sporting Goods Sees Q2 GAAP EPS $(0.90)-$(0.75)

<p>First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) reported quarterly earnings of $1.95 per share which missed the analyst consensus estimate of $2.63 by 25.86 percent. This is a 11.36 percent decrease over earnings of $2.20 per share from the same period last year.  The company reported quarterly sales of $844.57 million which beat the analyst consensus estimate of $839.28 million by 0.63 percent.  This is a 6.35 percent increase over sales of $794.11 million the same period last year.</p>


FSLR

First Solar Q1 EPS $1.95 Misses $2.63 Estimate, Sales $844.57M Beat $839.28M Estimate

<p>NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate NCS Multistage Holdings to report an <strong>earnings per share</strong> (EPS) of $0.64.</p>
<p>Investors in NCS Multistage Holdings are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<p>Here's a look at NCS Multistage Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td></td>
<td>1.27</td>
<td>-1.23</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.27</td>
<td>1.50</td>
<td>-1.03</td>
<td>0.99</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>Tracking NCS Multistage Holdings's Stock Performance</h3>
<p>Shares of NCS Multistage Holdings were trading at $30.23 as of April 28. Over the last 52-week period, shares are up 69.2%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/NCSM/earnings"><strong>To track all earnings releases for NCS Multistage Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


NCSM

Exploring NCS Multistage Holdings's Earnings Expectations

<p>Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) is looking for Q1 Adj EPS of $0.50-$0.75 vs $0.59 analyst estimate. sees sales of $750.000 million-$800.000 million vs $756.37 million analyst estimate.</p>


QRVO

Qorvo Sees Q1 Adj EPS $0.50-$0.75 vs $0.59 Est; Sees Sales $750.000M-$800.000M vs $756.37M Est

<p>ExlService Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXLS#NASDAQ">EXLS</a>) affirms FY2025 Adj EPS guidance from $1.83-$1.89 to $1.83-$1.89 vs $1.87 analyst estimate. Raises FY2025 sales outlook from $2.02 billion-$2.06 billion to $2.04 billion-$2.06 billion vs $2.05 billion estimate.</p>


EXLS

ExlService Hldgs Affirms FY2025 Adj EPS Guidance of $1.83-$1.89 vs $1.87 Est; Raises FY2025 Sales Guidance from $2.02B-$2.06B to $2.04B-$2.06B vs $2.05B Est

<p>Unifi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UFI#NYSE">UFI</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Unifi will report an <strong>earnings per share</strong> (EPS) of $-0.60.</p>
<p>Anticipation surrounds Unifi's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.31, leading to a 10.1% drop in the share price on the subsequent day.</p>
<p>Here's a look at Unifi's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.55</td>
<td>-0.25</td>
<td>-0.21</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.86</td>
<td>-0.42</td>
<td>-0.22</td>
<td>-0.57</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-10.0%</td>
<td>-11.0%</td>
<td>17.0%</td>
<td>16.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956974_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Unifi were trading at $5.35 as of April 28. Over the last 52-week period, shares are down 10.89%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/UFI/earnings"><strong>To track all earnings releases for Unifi visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Preview: Unifi's Earnings

<p>Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.00 by 42 percent. This is a 2.16 percent increase over earnings of $1.39 per share from the same period last year.  The company reported quarterly sales of $869.50 million which beat the analyst consensus estimate of $850.39 million by 2.25 percent.  This is a 7.70 percent decrease over sales of $941.99 million the same period last year.</p>


Qorvo Q4 Adj. EPS $1.42 Beats $1.00 Estimate, Sales $869.50M Beat $850.39M Estimate

BBIO

BridgeBio Pharma Q1 EPS $(0.88) Beats $(0.97) Estimate, Sales $116.60M Beat $61.94M Estimate

<p>-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 --</p>
<p>-- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with the anti-TL1A drug class --</p>
<p>-- XmAb942 half-life supports a 12-week maintenance dosing interval in XENITH-UC --</p>
<p>-- Lead selection for XmAb TL1A x IL23p19 program on track for first-in-human study start in 2026 --</p>
<p>-- Management hosting webcast and conference call at 5:00 p.m. ET / 2:00 p.m. PT today --</p>
<p>Xencor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XNCR#NASDAQ">XNCR</a>), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results from its first-in-human study of XmAb942, a high-potency, extended half-life, investigational anti-TL1A antibody in clinical development for patients with inflammatory bowel disease (IBD), such as ulcerative colitis (UC) and Crohn's disease (CD). Interim results from the healthy volunteer dose-escalation study indicate that XmAb942 is well tolerated at single and multiple doses. Pharmacokinetic analysis of the single dose cohorts estimates a human half-life of greater than 71 days for XmAb942, which supports a 12-week dosing interval during maintenance treatment.</p>
<p>Based on these positive interim results, Xencor is initiating the XENITH clinical program, advancing XmAb942 into a Phase 2b study in patients with moderate-to-severely active UC (XENITH-UC), with the expected study start in the second half of 2025.</p>
<p>Lead selection for Xencor's XmAb TL1A x IL23p19 bispecific antibody continues to advance. New <i>in vitro </i>studies show that several lead candidates match the target inhibition potency of commercial monospecific antibodies, but in a simple bispecific immunoglobulin G (IgG) format. Currently, these candidates are in final lead selection studies and manufacturing, in parallel, to prepare for the first-in-human study planned for 2026.</p>
<p>"Our Phase 1 data for XmAb942 validate our design goals for a best-in-class anti-TL1A therapy, combining high potency with less frequent dosing to potentially improve clinical outcomes and convenience for patients living with inflammatory bowel disease," said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. "We are excited to start our Phase 2b XENITH-UC trial later this year to efficiently support dose selection for pivotal studies, and we are poised to select our TL1A x IL23p19 bispecific lead candidate for an anticipated Phase 1 start in 2026. These and other milestones across our clinical portfolio are supported by our strong cash position."</p>
<p><strong>Key Highlights From Phase 1 Study Interim Results</strong></p>
<p>The Phase 1 study of XmAb942 in healthy volunteers is a randomized, double-blind, placebo-controlled, dose-escalation trial, exploring intravenous (IV) and subcutaneous (SC) dose administration, at three escalating dose levels. The interim results reflect analyses with subjects in single dose cohorts (IV, n=24; SC, n=24) and in multiple dose cohorts (IV, n=16).</p>
<ul>
<li>Safety: The blinded interim safety analysis indicates that all dose levels and routes of administration of treatment were well tolerated. No serious adverse events were observed, and no adverse events led to discontinuation from the study. The study remains blinded until follow-up is completed for the multiple dose portion of the study.</li>
<li>Pharmacokinetics: The interim analysis of single dose cohorts produced a half-life estimate of greater than 71 days, which is in line with expectations from the 23-day half-life in non-human primates and scaling metrics for half-life extended antibodies.</li>
<li>Pharmacodynamics: Consistent with XmAb942's high-potency and extended exposure design, large and durable dose-dependent increases of <i>total TL1A</i> in circulation were observed in both IV and SC cohorts. Circulating <i>free TL1A</i> was reduced significantly compared to placebo for all cohorts.</li>
<li>Immunogenicity: Early pharmacokinetic analysis of single and multiple dose cohorts shows no apparent evidence of anti-drug antibodies emerging against XmAb942.</li>
</ul>
<p><strong>XENITH-UC: Phase 2b Study in Ulcerative Colitis (UC)</strong></p>
<p>The Phase 2b study of XmAb942 in UC (XENITH-UC) will be a randomized, double-blind, placebo-controlled trial in patients with moderate-to-severely active UC, whose disease has progressed after at least one conventional or advanced therapy. XmAb942 will be administered intravenously during the 12-week induction period and subcutaneously every 12 weeks during the maintenance period. The primary endpoint of the study will be clinical remission based on the modified Mayo score at week 12. The study is designed to enroll approximately 220 patients across three induction dose levels and powered to enable Phase 3 dose selection. XENITH-UC is expected to start in the second half of 2025.</p>


Biotech

General

XNCR

Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study Of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody For Treatment Of Inflammatory Bowel Disease

<p>AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.23) by 39.13 percent. This is a 44 percent increase over losses of $(0.25) per share from the same period last year.  The company reported quarterly sales of $123.62 million which beat the analyst consensus estimate of $122.92 million by 0.57 percent.  This is a 13.57 percent increase over sales of $108.85 million the same period last year.</p>


ATRC

AtriCure Q1 Adj. EPS $(0.14) Beats $(0.23) Estimate, Sales $123.62M Beat $122.92M Estimate

<p>Onity Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONIT#NYSE">ONIT</a>) will release its quarterly earnings report on Wednesday, 2025-04-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Onity Group to report an <strong>earnings per share</strong> (EPS) of $1.87.</p>
<p>The announcement from Onity Group is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.22, leading to a 0.92% drop in the share price the following trading session.</p>
<p>Here's a look at Onity Group's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.35</td>
<td>1.27</td>
<td>1.36</td>
<td>1.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.13</td>
<td>2.65</td>
<td>1.33</td>
<td>3.74</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-1.0%</td>
<td>0.0%</td>
<td>-9.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956944_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Onity Group were trading at $34.34 as of April 28. Over the last 52-week period, shares are up 45.18%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ONIT/earnings"><strong>To track all earnings releases for Onity Group visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ONIT

What to Expect from Onity Group's Earnings

<p><strong>Stoneridge</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Stoneridge will report an <strong>earnings per share</strong> (EPS) of $-0.05. </p>
<p>The announcement from Stoneridge is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>Last quarter the company missed EPS by $0.14, which was followed by a 20.71% increase in the share price the next day.</p>
<p>Here's a look at Stoneridge's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>0.08</td>
<td>-0.02</td>
<td>-0.04</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.18</td>
<td>-0.24</td>
<td>0.17</td>
<td>-0.09</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>21.0%</td>
<td>-25.0%</td>
<td>6.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956934_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Stoneridge were trading at $3.94 as of April 28. Over the last 52-week period, shares are down 73.73%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analysts' Take on Stoneridge</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Stoneridge.</p>
<p>Analysts have provided Stoneridge with 4 ratings, resulting in a consensus rating of Outperform. The average one-year price target stands at $16.0, suggesting a potential 306.09% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of REE Automotive, Worksport and Holley, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for REE Automotive, with an average 1-year price target of $11.75, suggesting a potential 198.22% upside.</li>
<li>Analysts currently favor an Buy trajectory for Worksport, with an average 1-year price target of $11.5, suggesting a potential 191.88% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Holley, with an average 1-year price target of $3.88, suggesting a potential 1.52% downside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for REE Automotive, Worksport and Holley are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stoneridge</td>
<td>Outperform</td>
<td>-4.91%</td>
<td>$42.66M</td>
<td>-2.37%</td>
</tr>
<tr>
<td>REE Automotive</td>
<td>Buy</td>
<td>-94.76%</td>
<td>$-343K</td>
<td>-63.83%</td>
</tr>
<tr>
<td>Worksport</td>
<td>Buy</td>
<td>248.81%</td>
<td>$324.39K</td>
<td>-25.47%</td>
</tr>
<tr>
<td>Holley</td>
<td>Outperform</td>
<td>-10.05%</td>
<td>$63.89M</td>
<td>-8.59%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Stoneridge ranks at the bottom for Revenue Growth and Gross Profit, with negative growth and profit margin. It also has the lowest Return on Equity among its peers. However, it is not the worst performer in terms of Revenue Growth.</p>
<h3>About Stoneridge</h3>
<p>Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Its geographic segments include America, South America, Europe and Other.</p>
<h3>Financial Milestones: Stoneridge's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Stoneridge faced challenges, resulting in a decline of approximately <strong>-4.91%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Stoneridge's net margin excels beyond industry benchmarks, reaching <strong>-2.8%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Stoneridge's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-2.37%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Stoneridge's ROA excels beyond industry benchmarks, reaching <strong>-0.95%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Stoneridge's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.85</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<p><a href="https://www.benzinga.com/quote/SRI/earnings"><strong>To track all earnings releases for Stoneridge visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Preview Of Stoneridge's Earnings

<p>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) reported quarterly losses of $(0.78) per share. This is a 105.26 percent decrease over losses of $(0.38) per share from the same period last year.  The company reported $175.65 million in sales this quarter. This is a 9.19 percent decrease over sales of $193.43 million the same period last year.</p>


Big 5 Sporting Goods Q1 EPS $(0.78) Down From $(0.38) YoY, Sales $175.65M Down From $193.43M YoY

NMIH

NMI Holdings Q1 Adj. EPS $1.28 Beats $1.10 Estimate, Sales $173.25M Beat $151.63M Estimate

<p>Unisys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UIS#NYSE">UIS</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Unisys will report an <strong>earnings per share</strong> (EPS) of $-0.22.</p>
<p>The announcement from Unisys is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>In the previous earnings release, the company beat EPS by $0.03, leading to a 11.21% drop in the share price the following trading session.</p>
<p>Here's a look at Unisys's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.30</td>
<td>0.13</td>
<td>-0.01</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.33</td>
<td>-0.08</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-11.0%</td>
<td>34.0%</td>
<td>-8.0%</td>
<td>-8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745956925_0.png" alt="eps graph" /></p>
<h3>Unisys Share Price Analysis</h3>
<p>Shares of Unisys were trading at $3.98 as of April 28. Over the last 52-week period, shares are down 23.9%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/UIS/earnings"><strong>To track all earnings releases for Unisys visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Outlook For Unisys

Health Care

Press Releases

U.S. FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting

ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age

Comments

Arcutis Biotherapeutics

ニュース

最新ニュース Arcutis Biotherapeutics (NASDAQ:ARQT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル